RTP Mobile Logo
Select Publications

Keynote Session: Chronic Lymphocytic Leukemia

Anthony R Mato, MD, MSCE

Burger JA et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia 2020;34(3):787-98. Abstract

Burger JA et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 2015;373(25):2425-37. Abstract

Eichhorst B et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): An international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 2016;17(7):928-42. Abstract

Fischer K et al. Effect of fixed-duration venetoclax plus obinutuzumab (VenG) on progression-free survival (PFS), and rates and duration of minimal residual disease negativity (MRD–) in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) and comorbidities. ASCO 2019;Abstract 7502.

Fischer K et al. Quantitative analysis of minimal residual disease (MRD) shows high rates of undetectable MRD after fixed-duration chemotherapy-free treatment and serves as surrogate marker for progression-free survival: A prospective analysis of the randomized CLL14 trial. ASH 2019;Abstract 36.

Goede V et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014;370(12):1101-10. Abstract

Hallek M et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 2018;131(25):2745-60. Abstract

Hallek M et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 2010;376(9747):1164-74. Abstract

Moreno C et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2019;20(1):43-56. Abstract

Shanafelt TD et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemiaN Engl J Med 2019;381(5):432-43. Abstract

Sharman JP et al. ELEVATE TN: Phase 3 study of acalabrutinib combined with obinutuzumab (O) or alone vs O plus chlorambucil (Clb) in patients (Pts) with treatment-naive chronic lymphocytic leukemia (CLL). ASH 2019;Abstract 31.

Woyach JA et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med 2018;379(26):2517-28. Abstract

Kerry Rogers, MD

Byrd JC et al. Acalabrutinib in treatment-naïve (TN) chronic lymphocytic leukemia (CLL): Updated results from the phase 1/2 ACE-CL-001 study. ASH 2018;Abstract 692.

Byrd JC et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med 2016;374(4):323-32. Abstract

Furman RR et al. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: 42-month follow-up of a phase 2 study. ASH 2019;Abstract 3039.

Ghia P et al. ASCEND phase 3 study of acalabrutinib vs investigator’s choice of rituximab plus idelalisib (IDR) or bendamustine (BR) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). EHA 2019;Abstract LB2606.

Mato AR et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: A real-world analysis. Haematologica 2018;103(5):874-9. Abstract

Sharman JP et al. ELEVATE TN: Phase 3 study of acalabrutinib combined with obinutuzumab (O) or alone vs O plus chlorambucil (Clb) in patients (Pts) with treatment-naive chronic lymphocytic leukemia (CLL). ASH 2019;Abstract 31.

Woyach JA et al. BTK C481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia. J Clin Oncol 2017;35(13):1437-43. Abstract

Matthew S Davids, MD, MMSc

Dreger P et al. High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: Integrating molecular and cellular therapies. Blood 2018;132(9):892–902. Abstract

Flinn IW et al. The phase 3 DUO trial: Duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood 2018;132(23):2446-55. Abstract

Jones JA et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: An interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 2018;19(1):65-75. Abstract

Mato AR et al. Treatment sequences and outcomes of patients with CLL treated with venetoclax and other novel agents post introduction of novel therapies. ASH 2019;Abstract 1756.

O’Brien S et al. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: A 5-year experience. Blood 2018;131(17):1910-9. Abstract

Roberts AW et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med 2016;374(4):311-22. Abstract

Seymour JF et al. Four-year analysis of MURANO study confirms sustained benefit of time-limited venetoclax-rituximab (VenR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). ASH 2019;Abstract 355

Sharman JP et al. Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia. J Clin Oncol 2019;37(16):1391-402. Abstract

Soumerai JD et al. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: A retrospective, pooled cohort study with external validations. Lancet Haematol 2019;6(7):e366-74. Abstract

Wierda WG et al. Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. Br J Haematol 2019;186(1):184-8. No abstract available

Module 1: Colorectal and Gastric Cancer

Chalmers ZR et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 2017;9(1):34. Abstract

Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study: A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer. NCT02997228

Diaz LA et al. KEYNOTE-177: Phase 3, open-label, randomized study of first-line pembrolizumab (Pembro) versus investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC). Gastrointestinal Cancers Symposium 2018;Abstract TPS877.

Giannakis M et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep 2016;15(4):857-65. Abstract

Kim T-M et al. The landscape of microsatellite instability in colorectal and endometrial cancer genomes. Cell 2013;155(4):858-68. Abstract

Kloor M, von Knebel Doeberitz M. The immune biology of microsatellite-unstable cancer. Trends Cancer 2016;2(3):121-33. Abstract

Le DT et al. Programmed death-1 blockade in mismatch repair deficient colorectal cancer. ASCO 2016;Abstract 103.

Le DT et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372(26):2509-20. Abstract

Lenz H-J et al. Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). ESMO 2018;Abstract LBA18_PR.

Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature 2012;481(7381):287-294. Abstract

Niu B et al. MSIsensor: Microsatellite instability detection using paired tumor-normal sequence data. Bioinformatics 2014;30(7):1015-6. Abstract

Overman MJ et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol 2018;36(8):773-9. Abstract

Overman MJ et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study. Lancet Oncol 2017;18(9):1182-91. Abstract

Overman MJ et al. Where we stand with immunotherapy in colorectal cancer: Deficient mismatch repair, proficient mismatch repair, and toxicity management. Am Soc Clin Oncol Educ Book 2018;38:239-47. Abstract

POLEM: Avelumab plus 5-FU based chemotherapy as adjuvant treatment for stage 3 MSI-high or POLE exonuclease domain mutant colon cancer: A phase 3 randomised study. NCT03827044

Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair. NCT02912559

Sepulveda AR et al. Molecular biomarkers for the evaluation of colorectal cancer: Guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. J Clin Oncol 2017;35(13):1453-86. Abstract

Wang Q et al. Molecular classification of gastric adenocarcinoma. Gastroenterology Res 2019;12(6):275-82. Abstract

Module 2: Hepatocellular Carcinoma and Pancreatic Cancer

Abou-Alfa GK et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 2018;379(1):54-63. Abstract

Bruix J et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389(10064):56-66. Abstract

Cancer Genome Atlas Research Network. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 2017;32(2):185-203. Abstract

Cheng A et al. IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). ESMO Asia 2019;Abstract 1062.

Fatima J et al. Pancreatoduodenectomy for ductal adenocarcinoma: Implications of positive margin on survival. Arch Surg 2010;145(2):167-72. Abstract

Finn RS et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: A randomized, double-blind, phase III trial. J Clin Oncol 2020;38(3):193-202. Abstract

Kindler HL et al. Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial. ASCO 2019;Abstract LBA4.

Konstantinidis IT et al. Pancreatic ductal adenocarcinoma: Is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection? Ann Surg 2013;257(4):731-6. Abstract

Llovet JM et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-90. Abstract

Tempero MA et al. APACT: Phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma. ASCO 2019;Abstract 4000.

Yau T et al. CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). ESMO 2019;Abstract LBA38_PR.

Yau T et al. Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. ASCO 2019;Abstract 4012.

Module 3: Dermatologic Cancers

Ascierto PA et al. Update on tolerability and overall survival in COLUMBUS: Landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. Eur J Cancer 2020;126:33-44. Abstract

Davies MA et al. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): A multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol 2017;18(7):863-73. Abstract

Dummer R et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2018;19(5):603-15. Abstract

Eggermont AMM et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 2018;378(19):1789-801. Abstract

Eggermont AMM et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med 2016;375(19):1845-55. Abstract

Long GV et al. Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600-mutant stage III melanoma. ESMO 2018;Abstract LBA43.

Long GV et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med 2017;377(19):1813-23. Abstract

Menzies AM et al. Phase 2 study of neoadjuvant dabrafenib + trametinib (D + T) for resectable stage IIIB/C BRAF V600 mutant melanoma. ESMO 2017;Abstract 1220PD.

Migden MR et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: Results from an open-label, phase 2, single-arm trial. Lancet Oncol 2020;21(2):294-305. Abstract

Nghiem P et al. Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy. J Clin Oncol 2019;37(9):693-702. Abstract

Robert C et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015;372(26):2521-32. Abstract

Rozeman EA et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): A multicentre, phase 2, randomised, controlled trial. Lancet Oncol 2019;20(7):948-60. Abstract

Schadendorf D et al. Adjuvant immunotherapy with nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma patients with no evidence of disease (NED): A randomized, double-blind phase 2 trial (IMMUNED). ESMO 2019;Abstract LBA67.

Schadendorf D et al. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): A randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2019;20(5):701-10. Abstract

Tawbi HA et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med 2018;379(8):722-30. Abstract

Weber JS et al. Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase 3 CheckMate 238 trial. ESMO 2019;Abstract 1310O.

Module 4: Hodgkin and Non-Hodgkin Lymphomas

Bachy E et al. A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood 2018;132(1):49-58. Abstract

Bartlett NL et al. Brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma (cHL): 4-year update of the Echelon-1 study. ASH 2019;Abstract 4026.

Cheson BD et al. Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. J Clin Oncol 2018;36(22):2259-66. Abstract

Connors JM et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma. N Engl J Med 2018;378(4):331-44. Abstract

Dreyling M et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol 2017;35(35):3898-905. Abstract

Friedberg JW. Progress in advanced-stage follicular lymphoma. J Clin Oncol 2018;36(23):2363-5. No abstract available

Horwitz S et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): A global, double-blind, randomised, phase 3 trial. Lancet 2019;393(10168):229-40. Abstract

Huet S et al. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: A retrospective training and validation analysis in three international cohorts. Lancet Oncol 2018;19(4):549-61. Abstract

Jurinovic V et al. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood 2016;128(8):1112-20. Abstract

Leonard JP et al. AUGMENT: A phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol 2019;37(14):1188-99. Abstract

Leonard JP et al. Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance). J Clin Oncol 2015;33(31):3635-40. Abstract

Sehn LH et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): A randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol 2016;17(8):1081-93. Abstract

Trotman J et al. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): Secondary analysis of a randomised, phase 3 trial. Lancet Oncol 2018;19(11):1530-42. Abstract

Wang ML et al. Frontline treatment with ibrutinib plus rituximab (IR) followed by short course R-hypercvad/MTX is extremely potent and safe in patients (age ≤65 years) with mantle cell lymphoma (MCL) — Results of phase-II Window-1 clinical trial. ASH 2019 Abstract 3987.

Module 5: Diffuse Large B-Cell Lymphoma/Chimeric Antigen Receptor T-Cell Therapy

Abramson JS et al. Pivotal safety and efficacy results from Transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) large B cell lymphomas. ASH 2019;Abstract 241.

Bachanova V et al. Impact of tisagenlecleucel chimeric antigen receptor (CAR)-T cell therapy product attributes on clinical outcomes in adults with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). ASH 2019;Abstract 242.

Crump M et al. Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study. Blood 2017;130(16):1800-8. Abstract

Lee DW et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 2019;25(4):625-38. Abstract

Locke FL et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1-2 trial. Lancet Oncol 2019;20(1):31-42. Abstract

Nastoupil LJ et al. Axicabtagene ciloleucel (axi-cel) CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory large B-cell lymphoma: Real world experience. ASH 2018;Abstract 91.

Neelapu SS et al. 2-year follow-up and high-risk subset analysis of Zuma-1, the pivotal study of axicabtagene ciloleucel (axi-cel) in patients with refractory large B cell lymphoma. ASH 2018;Abstract 2967.

Neelapu SS et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 2017;377(26):2531-44. Abstract

Neelapu SS et al. Long-term follow-up ZUMA-1: A pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL). ASH 2017;Abstract 578.

Schuster SJ et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2019;380(1):45-56. Abstract

Schuster SJ et al. Sustained disease control for adult patients with relapsed or refractory diffuse large B-cell lymphoma: An updated analysis of Juliet, a global pivotal phase 2 trial of tisagenlecleucel. ASH 2018;Abstract 1684.

Sehn LH et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2020;38(2):155-65. Abstract

Module 6: Acute Leukemias

Abou Dalle I et al. The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia. Ther Adv Hematol 2018;9(7):163-73. Abstract

Brown PA et al. A randomized phase 3 trial of blinatumomab vs. chemotherapy as post-reinduction therapy in high and intermediate risk (HR/IR) first relapse of B-acute lymphoblastic leukemia (B-ALL) in children and adolescents/young adults (AYAs) demonstrates superior efficacy and tolerability of blinatumomab: A report from Children's Oncology Group study AALL1331. ASH 2019;Abstract LBA-1.

Daver N et al. Targeting FLT3 mutations in AML: Review of current knowledge and evidence. Leukemia 2019;33(2):299-312. Abstract

DiNardo CD, Wei AH. How I treat acute myeloid leukemia in the era of new drugs. Blood 2020;135(2):85-96. Abstract

DiNardo CD et al. Enasidenib plus azacitidine significantly improves complete remission and overall response compared with azacitidine alone in patients with newly diagnosed acute myeloid leukemia (AML) with isocitrate dehydrogenase 2 (IDH2) mutations: Interim phase II results from an ongoing, randomized study. ASH 2019;Abstract 643.

DiNardo CD et al. Venetoclax combined with decitabine or azacitidine in treatment-naïve, elderly patients with acute myeloid leukemia. Blood 2019;133(1):7-17. Abstract

Fathi AT et al. Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2: Analysis of a phase 1/2 study. JAMA Oncol 2018;4(8):1106-10. Abstract

Gökbuget N et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood 2018;131(14):1522-31. Abstract

Jonas BA, Pollyea DA. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Leukemia 2019;33(12):2795-804. Abstract

Kantarjian H et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 2017;376(9):836-47. Abstract

Kiyoi H et al. FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development. Cancer Sci 2020;111(2):312-22. Abstract

Lancet J et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol 2018;36(26):2684-92. Abstract

Maiti A et al. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent with venetoclax regimens. ASH 2019;Abstract 738.

Maude SL et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 2018;378(5):439-48. Abstract

Perl AE et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med 2019;381(18):1728-40. Abstract

Pratz KW et al. Outcomes after stem cell transplant in older patients with acute myeloid leukemia treated with venetoclax-based therapies. ASH 2019;Abstract 264.

Short NJ et al. Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia. Ther Adv Hematol 2019;[Online ahead of print]. Abstract

Wei AH et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: Results from a phase Ib/II study. J Clin Oncol 2019;37(15):1277-84. Abstract

Module 7: Gynecologic Cancers

Burger RA et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365(26):2473-83. Abstract

Chung HC et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: Results from the phase II KEYNOTE-158 study. J Clin Oncol 2019;37(17):1470-8. Abstract

Clamp AR et al. ICON8: A GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: Results of primary progression-free survival (PFS) analysis. ESMO 2017;Abstract 929O_PR.

Coleman RL et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med 2019;381(25):2403-15. Abstract

Coleman RL et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;390(10106):1949-61. Abstract

González-Martín A et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2019;381(25):2391-402. Abstract

González-Martín A et al. Niraparib therapy in patients with newly diagnosed advanced ovarian cancer (PRIMA/ENGOT-OV26/GOG-3012 study). ESMO 2019;Abstract LBA1.

Gourley C et al. Analysis of tumor samples from SOLO1: Frequency of BRCA specific loss of heterozygosity (LOH) and progression-free survival (PFS) according to homologous recombination repair deficiency (HRD)-LOH score. ESMO 2019;Abstract 998PD.

Ledermann J et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014;15(8)852-61. Abstract

Makker V et al. Lenvatinib + pembrolizumab in patients with advanced endometrial cancer: Updated results. ASCO 2018;Abstract 5596.

Mirza MR et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 2016;375(22):2154-64. Abstract

Moore K et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2018;379(26):2495-505. Abstract

Oaknin A et al. Preliminary safety, efficacy, and pharmacokinetic/pharmacodynamic characterization from GARNET, a phase I/II clinical trial of the anti–PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-h and MSS endometrial cancer. SGO 2019;Abstract 33.

Perren TJ et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365(26):2484-96. Abstract

Ray-Coquard I et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 2019;381(25):2416-28. Abstract

Ray-Coquard IL et al. Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. ESMO 2019;Abstract LBA2_PR.

Module 8: ER-Positive, HER2-Negative Breast Cancer

Cristofanilli M et al. Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Analyses from PALOMA-3. Ann Oncol 2018;29(Suppl 8):viii708. Abstract

Dickler MN et al. MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer. Clin Cancer Res 2017;23(17):5218-24. Abstract

Hortobagyi GN et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol 2018;29(7):1541-7. Abstract

Im SA et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med 2019;381(4):307-16. Abstract

Johnston S et al. MONARCH 3 final PFS: A randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer 2019;5:5. Abstract

Juric D et al. Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the phase III SOLAR-1 trial. San Antonio Breast Cancer Symposium 2018;Abstract GS3-08.

Rugo HS et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat 2019;174(3):719-29. Abstract

Rugo HS et al. Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: A pooled analysis of randomised PALOMA clinical studies. Eur J Cancer 2018;101:123-33. Abstract

Sledge GW Jr et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: A randomized clinical trial. JAMA Oncol 2019;[Online ahead of print]. Abstract

Tripathy D et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): A randomised phase 3 trial. Lancet Oncol 2018;19(7):904-15. Abstract

Turner NC et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med 2018;379(20):1926-36. Abstract

Module 9: HER2-Positive and Triple-Negative Breast Cancer

Emens LA et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: A phase 1 Study. JAMA Oncol 2019;5(1):74-82. Abstract

Gianni L et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study. San Antonio Breast Cancer Symposium 2019;Abstract GS3-04.

Loibl S et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: Clinical results and biomarker analysis of GeparNuevo study. Ann Oncol 2019;30(8):1279-88. Abstract

Martin M et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2017;18(12):1688-700. Abstract

Modi S et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med 2020;382(7):610-21. Abstract

Murthy RK et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med 2020;82(7):597-609. Abstract

Nanda R et al. Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib KEYNOTE-012 study. J Clin Oncol 2016;34(21):2460-7. Abstract

Piccart M et al. Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive early breast cancer. San Antonio Breast Cancer Symposium 2019;Abstract GS1-04.

Saura C et al. Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial. ASCO 2019;Abstract 1002.

Schmid P et al. KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early triple-negative breast cancer: Pathologic complete response in key subgroups and by treatment exposure, residual cancer burden, and breast-conserving surgery. San Antonio Breast Cancer Symposium 2019;Abstract GS3-03.

Schmid P et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 2018;379(22):2108-21. Abstract

Tolaney SM et al. TBCRC 033: A randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2-positive breast cancer (BC) (ATEMPT). San Antonio Breast Cancer Symposium 2019;Abstract GS1-05.

von Minckwitz G et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 2019;380(7):617-28. Abstract

Module 10: Prostate Cancer

Abida W et al. Preliminary results from TRITON2: A phase II study of rucaparib in patients with mCRPC associated with homologous recombination repair gene alterations. ESMO 2018;Abstract 793PD.

Armstrong AJ et al. ARCHES: A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol 2019;37(32):2974-86. Abstract

Armstrong AJ et al. Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: The PROPHECY study. J Clin Oncol 2019;37(13):1120-9. Abstract

Chi KN et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 2019;381(1):13-24. Abstract

Davis ID et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 2019;381(2):121-31. Abstract

de Wit R et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med 2019;381(26):2506-18. Abstract

Fizazi K et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2019;380(13):1235-46. Abstract

Fizazi K et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;377(4):352-60. Abstract

Hussain M et al. PROfound: Phase 3 study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations. ESMO 2019;Abstract LBA12.

Hussain M et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2018;378(26):2465-74. Abstract

Hussain M et al. PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC). Genitourinary Cancers Symposium 2018;Abstract 3.

James ND et al. Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: Data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). Eur Urol 2015;67(6):1028-38. Abstract

Khalaf DJ et al. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: A multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol 2019;20(12):1730-9. Abstract

Smith MR et al. Apalutamide (APA) and overall survival (OS) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Updated results from the phase III SPARTAN study. ESMO 2019;Abstract 843O.

Smith MR et al. Pre-specified interim analysis of GALAHAD: A phase 2 study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD). ESMO 2019;Abstract LBA50.

Smith MR et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 2018;378(15):1408-18. Abstract

Smith MR et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: Results of a phase 3, randomised, placebo-controlled trial. Lancet 2012;379(9810):39-46. Abstract

Smith MR et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005;23(13):2918-25. Abstract

Sweeney C et al. Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial. ASCO 2019;Abstract LBA2.

Sweeney CJ et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015;373(8):737-46. Abstract

Sydes MR et al. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: Directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol 2018;29(5):1235-48. Abstract

VanderWeele DJ et al. Metastatic hormone-sensitive prostate cancer: Clinical decision making in a rapidly evolving landscape of life-prolonging therapy. J Clin Oncol 2019;37(32):2961-7. Abstract

Module 11: Renal Cell Carcinoma and Bladder Cancer

Choueiri TK et al. Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). ASCO 2019;Abstract 101.

Choueiri TK et al. Subgroup analysis from JAVELIN Renal 101: Outcomes for avelumab plus axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). Genitourinary Cancers Symposium 2019;Abstract 544.

Choueiri TK et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): Final results from a randomised, open-label, phase 3 trial. Lancet Oncol 2016;17(7):917-27. Abstract

de Wit R et al. Pembrolizumab for high-risk non–muscle invasive bladder cancer unresponsive to bacillus Calmette-Guérin: Phase 2 KEYNOTE-057 trial. ESMO 2018;Abstract 864O.

Loriot Y et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med 2019;381(4):338-48. Abstract

Motzer RJ et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380(12):1103-15. Abstract

Motzer RJ et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: A randomised, phase 2, open-label, multicentre trial. Lancet Oncol 2015;16(15):1473-82. Abstract

Motzer RJ et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373(19):1803-13. Abstract

Motzer RJ et al; CheckMate 214 Investigators. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: Extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol 2019;20(10):1370-85. Abstract

Rini BI et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): A multicenter, open-label, phase 3, randomized controlled trial. Lancet 2019;393(10189):2404-15. Abstract

Rini BI et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal cell carcinoma. N Engl J Med 2019;380(12):1116-27. Abstract

Rosenberg JE et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. J Clin Oncol 2019;37(29):2592-600. Abstract

Siefker-Radtke AO et al. First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt). Genitouriniary Cancers Symposium 2018;Abstract 4503.

Module 12: Head and Neck Cancer

Argiris A et al. Phase III randomized trial of chemotherapy with or without bevacizumab (B) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Survival Analysis of E1305, an ECOG-ACRIN Cancer Research Group trial. ASCO 2017;Abstract 6000.

Burtness B et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study. Lancet 2019;394(10212):1915-28. Abstract

Burtness B et al. KEYNOTE-048: Phase 3 study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). ESMO 2018;Abstract LBA8_PR.

Cohen EEW et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): A randomised, open-label, phase 3 study. Lancet 2019;393(10167):156-67. Abstract

Ferris RL et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016;375(19):1856-67. Abstract

Gillison ML et al. Nivolumab (Nivo) vs investigator’s choice (IC) for platinum-refractory (PR) recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN; Checkmate 141): Outcomes in first-line (1L) R/m patients and updated safety and efficacy. ASCO 2017;Abstract 6019.

Licitra LF et al. EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). ASCO 2019;Abstract 6012.

Seiwert TY et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial. Lancet Oncol 2016;17(7):956-65. Abstract

Taylor MH et al. A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with squamous cell carcinoma of the head and neck. ASCO 2018;Abstract 6016.

Vermorken JB et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359(11):1116-27. Abstract

Module 13: Multiple Myeloma

Chauhan D et al. In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells. Clin Cancer Res 2013;19(11):3019-31. Abstract

Harrison S et al. T(11;14) and high BCL2 expression are predictive biomarkers of response to venetoclax in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma: Biomarker analyses from the phase 3 Bellini study. ASH 2019
;Abstract 142.

Hitzerd SM et al. Positioning of aminopeptidase inhibitors in next generation cancer therapy. Amino Acids 2014;46(4):793-808. Abstract

Kumar S et al. A phase 3 study of venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. EHA 2019;Abstract LB2601.

Kumar S et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood 2017;130(22):2401-9. Abstract

Lonial S et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomized, open-label, phase 2 study. Lancet Oncol 2019;21(2):207-21. Abstract

Madduri D et al. Results from CARTITUDE-1: A phase 1b/2 Ssudy of JNJ-4528, a CAR-T cell therapy directed against B-cell maturation antigen (BCMA), in patients with relapsed and/or refractory multiple myeloma (R/R MM). ASH 2019;Abstract 577.

Matyskiela ME et al. A cereblon modulator (CC-220) with improved degradation of Ikaros and Aiolos. J Med Chem 2018;61(2):535-42. Abstract

Moore HE et al. Aminopeptidase inhibition as a targeted treatment strategy in myeloma. Mol Cancer Ther 2009;8(4):762-70. Abstract

Moreau P et al. Updated analysis of Bellini, a phase 3 study of venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. ASH 2019
;Abstract 1888.

Raje N et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med 2019;380(18):1726-37. Abstract

Ray A et al. A novel alkylating agent melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells. Br J Haematol 2016;174(3):397-409. Abstract

Wang BY et al. Long-term follow-up of a phase 1, first-in-human open-label study of LCAR-B38M, a structurally differentiated chimeric antigen receptor T (CAR-T) cell therapy targeting B-cell maturation antigen (BCMA), in patients (pts) with relapsed/refractory multiple myeloma (RRMM). ASH 2019
;Abstract 579.

Wickström M et al. Melflufen - a peptidase-potentiated alkylating agent in clinical trials. Oncotarget 2017;8(39):66641-55. Abstract

Wickström M et al. Aminopeptidase N (CD13) as a target for cancer chemotherapy. Cancer Sci 2011;102(3):501-8. Abstract

Module 14: Immune Checkpoint Inhibitors in Lung Cancer

A phase 3, randomized study of nivolumab plus ipilimumab in combination with chemotherapy vs chemotherapy alone as first line therapy in stage IV non-small cell lung cancer. NCT03215706

A phase III, randomized, multi-center, open-label, comparative global study to determine the efficacy of durvalumab or durvalumab and tremelimumab in combination with platinum-based chemotherapy for first-line treatment in patients with metastatic non small-cell lung cancer (NSCLC) (POSEIDON). NCT03164616

Anthonia SJ et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018;379(24):2342-50. Abstract

Borghaei H et al. Pembrolizumab plus chemotherapy for advanced NSCLC without tumor PD-L1 expression: Pooled analysis of KN021G, KN189 and KN407. WCLC 2019;Abstract MA25.01.

Gandhi L et al. KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC. AACR 2018;Abstract CT075.

Garon EB et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372(21):2018-28. Abstract

Hellmann MD et al. Nivolumab (nivo) + ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): Initial results from CheckMate 227. AACR 2018;Abstract CT077.

Horn L et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 2018;379(23):2220-9. Abstract

Liu S et al. IMPOWER 133: Primary PFS, OS and safety in a ph1/3 study of 1L atezolizumab + carboplatin + etoposide in extensive-stage SCLC. WCLC 2018;Abstract PL02.07.

Lopes G at al. Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study. ASCO 2018;Abstract LBA4.

Paz-Ares L et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomised, controlled, open-label, phase 3 trial. Lancet 2019;394(10212):1929-39. Abstract

Paz-Ares L et al. Overall survival with durvalumab plus etoposide-platinum in first-line extensive-stage SCLC: Results from the CASPIAN study. WCLC 2019;Abstract PL02.11.

Peters S et al. Nivolumab (nivo) + low-dose ipilimumab (ipi) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate-227 part 1 final analysis. ESMO 2019;Abstract LBA7128.

Reck M et al. IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC). ESMO 2019;Abstract 1736O.

Reck M et al. KEYNOTE-024 3-year survival update: Pembrolizumab vs platinum-based chemotherapy for advanced non–small-cell lung cancer. WCLC 2019;Abstract OA14.01.

Socinski M et al. Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC. ASCO 2018;Abstract 9002

Spigel D et al. IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC. ESMO 2019;Abstract LBA78.

Module 15: Targeted Treatment of Lung Cancer

Demetri GD et al. Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-FP) tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. ESMO 2018;Abstract LBA17.

Drilon A et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378(8):731-9. Abstract

Herbst RS et al. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): A double-blind, placebo-controlled, phase 3 trial. Lancet 2011;377(9780):1846-54. Abstract

Hyman DM et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 2015;373(8):726-36. Abstract

Kohutek ZA et al. Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases. J Neurooncol 2015;125(1):149-56. Abstract

Magnuson WJ et al. Management of brain metastases in tyrosine kinase inhibitor-naïve epidermal growth factor receptor-mutant non-small-cell lung cancer: A retrospective multi-institutional analysis. J Clin Oncol 2017;35(10):1070-7. Abstract

Nakagawa K et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): A randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019;20(12):1655-69. Abstract

Oxnard GR et al. Registrational results of LIBRETTO-001: A phase 1/2 trial of LOXO-292 in patients with RET fusion-positive lung cancers. IASLC WCLC 2019;Abstract PL02.08.

Planchard D et al. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E
-mutant metastatic non-small-cell lung cancer: An open-label, phase 2 trial.
 Lancet Oncol 2017;18(10):1307-16. Abstract

Planchard D et al. Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: A single-arm, multicentre, open-label, phase 2 trial. Lancet Oncol 2016;17(5):642-50. Abstract

Ramalingam SS et al. Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis. ESMO 2019;Abstract LBA5_PR.

Reungwetwattana T et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol 2018;[Online ahead of print]. Abstract

Saito H et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): Interim analysis of an open-label, randomised, multicentre, phase 3 trialLancet Oncol 2019;20(5):625-35. Abstract

Seto T et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): An open-label, randomised, multicentre, phase 2 study. Lancet Oncol 2014;15(11):1236-44. Abstract

Soria J-C et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018;378(2):113-25. Abstract

Stinchcombe TE et al. Effect of erlotinib plus bevacizumab vs erlotinib alone on progression-free survival in patients with advanced EGFR-mutant non-small cell lung cancer: A phase 2 randomized clinical trial. JAMA Oncol 2019;5(10):1448-55. Abstract